ADC vs Bispecific: 2026 Deal Benchmarks

Head-to-Head: ADC vs Bispecific Deal Economics

ADCs and bispecific antibodies are the two most active modalities in biopharma deal-making, together accounting for over 25% of all oncology licensing transactions in 2024-2026. Both are platform technologies capable of generating multiple clinical candidates from a single core technology. But their deal economics diverge meaningfully — and understanding why is critical for licensors, buyers, and investors.

Why ADCs Command a Premium

The 25-30% ADC upfront premium over bispecifics is driven by three structural factors that are unlikely to change in the near term:

1. Validated commercial models. Enhertu (Daiichi Sankyo/AstraZeneca) is on track for $10B+ peak sales. Padcev (Astellas/Seagen/Pfizer) exceeded $3B in its first full year post-bladder cancer approval. These commercial proof points give buyers confidence in the revenue assumptions that underpin ADC deal valuations. Bispecifics have growing commercial validation (teclistamab, glofitamab, mosunetuzumab), but have not yet produced a $5B+ revenue asset.

2. Platform scalability. An ADC platform — defined by its linker-payload technology — can be retargeted to 5-10+ tumor types by swapping the antibody component. This creates a portfolio effect: a single platform deal can encompass multiple clinical candidates. The Merck-Daiichi Sankyo collaboration ($4B upfront, $22B TDV) was structured as a platform access deal across three ADC programs. Bispecific platforms also offer scalability, but the engineering complexity of each new target pairing is higher.

3. Manufacturing scarcity. ADC manufacturing requires specialized conjugation facilities, payload synthesis capabilities, and quality control expertise that are concentrated in a small number of CDMOs (Lonza, Samsung Biologics, WuXi). This supply constraint creates a premium for companies that have secured manufacturing capacity — a factor that directly inflates deal valuations.

ADC Deal Market: 2019-2026

The ADC deal market has gone through three distinct phases: the pre-Seagen era (2019-2021), the mega-deal peak (2022-2023), and the normalized market (2024-2026). Understanding this evolution is essential for calibrating expectations.

Bispecific Antibody Momentum

While ADCs dominate on absolute deal value, bispecifics are the fastest-growing modality by deal count growth rate. Bispecific deal volume has approximately doubled from 2021 to 2025, driven by clinical validation of T-cell engagers in hematology and the emergence of novel bispecific formats in solid tumors and immunology.

The China-to-West Licensing Wave

One of the most significant developments in ADC deal-making since 2023 has been the China-to-West licensing wave. Chinese biotech companies — many of which built sophisticated ADC platforms during the 2020-2022 investment boom — are now licensing assets to Western pharma at terms that rival or exceed domestically-originated deals.

These deals share common characteristics: Phase 1 or early Phase 2 assets with novel payloads (topoisomerase I inhibitors, MMAE/MMAF alternatives, immunostimulatory payloads), targeting antigens with established clinical precedent (HER2, Trop-2, Nectin-4, B7-H3). Upfronts range from $50-200M with TDVs of $1-2B+, and most include manufacturing technology transfer provisions.

For ADC licensors globally, the China wave has two effects: it increases competition for buyer attention (more assets available), but it also validates the modality premium (buyers are willing to pay $100M+ upfronts for Phase 1 ADCs from Chinese companies they may have limited due diligence history with — a strong signal of modality conviction).

Where Bispecifics Close the Gap

Bispecifics outperform ADCs on deal economics in two specific contexts:

• Hematology. T-cell engaging bispecifics have become the dominant modality for relapsed/refractory multiple myeloma and B-cell lymphomas. In this space, bispecific upfronts and TDVs match or exceed ADC levels, because the clinical and commercial validation (teclistamab, glofitamab, epcoritamab) is equally strong.
• Immunology/autoimmune. Bispecific antibodies targeting two inflammatory cytokines (e.g., IL-4/IL-13, TNF/IL-17) are a growing category in immunology deal-making, where ADCs have limited relevance. These deals can command $200-500M upfronts at Phase 2 due to the large market opportunity in chronic inflammatory diseases.

Full Modality Comparison: Oncology Upfronts

Recent Mega-Deals: Case Studies

• Merck-Daiichi Sankyo (2024): $4B upfront, $22B TDV. ADC collaboration across three programs. The largest single upfront in ADC licensing history, reflecting platform-level conviction.
• AbbVie-ImmunoGen (2024): $10.1B acquisition. Single-asset ADC company (Elahere, ovarian cancer). Premium driven by first-in-class status and expanding label potential.
• Pfizer-Seagen (2023): $43B acquisition. The deal that reshaped ADC valuations permanently, pricing Seagen's 4-product ADC platform at 10x trailing revenue.
• BMS-BioNTech (2024): Bispecific collaboration. $1.2B upfront for multiple T-cell engaging bispecifics in solid tumors, demonstrating growing confidence in the format beyond hematology.
• AstraZeneca-Daiichi Sankyo (2023 expansion): $2B additional upfront to expand the Enhertu collaboration to additional tumor types. Platform expansion deal that validated the multi-indication ADC thesis.

Frequently Asked Questions

Why do ADCs command higher deal valuations than bispecifics?

ADCs benefit from validated commercial models (Enhertu approaching $10B+ peak sales), platform scalability across 5-10+ tumor types, and manufacturing scarcity that creates supply-side premium. The 25-30% upfront gap reflects these structural advantages.

What are typical ADC upfronts in 2026?

Median ADC upfront is $361M across all phases. Phase 2 ADC upfronts range from $200-600M depending on target differentiation, payload novelty, and therapeutic area. Platform deals (multiple targets) command $500M-$4B upfronts, as seen in the Merck-Daiichi collaboration.

How has the China licensing wave affected ADC deal terms?

Chinese-origin ADCs are being licensed to Western pharma at $50-200M upfronts for Phase 1-2 assets. This increases buyer options but also validates modality conviction. The wave has compressed deal timelines and created competitive dynamics that benefit all ADC licensors.

Are bispecific deal values catching up?

Bispecific deal volume is growing faster than ADC deal volume, but the absolute valuation gap has remained stable at 25-30%. Bispecifics are gaining in hematology and immunology, where they match or exceed ADC deal values. In solid tumors, ADCs retain the premium.

What modality has the highest deal valuations in oncology?

ADCs lead with $361M median upfront, followed by bispecifics ($281M), radiopharmaceuticals ($220M), and CAR-T for hematologic malignancies ($185M). Use the Ambrosia Benchmarker to model deal terms for your specific modality.